Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Nambiar (San Antonio, TX, United States of America), J. Justice (Winston-Salem, NC, United States of America), T. Tchkonia (Rochester, MN, United States of America), N. Lebrasseur (Rochester, MN, United States of America), R. Pascual (Winston-Salem, NC, United States of America), S. Hashmi (Rochester, MN, United States of America), L. Prata (Rochester, MN, United States of America), M. Masternak (Orlando, FL, United States of America), N. Musi (San Antonio, United States of America), S. Kritchevsky (Winston-Salem, NC, United States of America), J. Kirkland (Rochester, MN, United States of America). Late Breaking Abstract - Evaluating the feasibility, safety, and efficacy of senolytics in idiopathic pulmonary fibrosis. 244

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings Year: 2019 Late Breaking Abstract - Efficacy and safety of macitentan in portopulmonary hypertension: the PORTICO trial Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 Late Breaking Abstract - ND-L02-s0201 treatment leads to efficacy in preclinical IPF models Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Late Breaking Abstract: Non-steroid agents for idiopathic pulmonary fibrosis: A systematic review Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease Year: 2010 Late Breaking Abstract - Effectiveness and safety of mepolizumab in real-world clinical practice: the REALITI-A study Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 Late Breaking Abstract - Idiopathic Pulmonary Fibrosis – a worldwide review of ‘real’ life’ practice: experience from a treatment feasibility review in 41 countries Source: International Congress 2018 – ILDs: From bench to bedside Year: 2018 Late Breaking Abstract - Effects of a new airway clearance technology in children with cystic fibrosis - A homecare randomized controlled trial Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects Year: 2021 Late Breaking Abstract - Effects of pulmonary rehabilitation on major symptoms of long COVID (post-COVID-19 syndrome): preliminary results Source: Virtual Congress 2021 – A multidisciplinary approach to pulmonary rehabilitation and management of chronic respiratory diseases Year: 2021 Late Breaking Abstract - Long-term safety & durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Pharmacokinetics (PK) of nintedanib with add-on pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): results from INJOURNEY Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 Pirfenidone post-authorization safety registry (PASSPORT) update Source: International Congress 2015 – Treatment of IPF Year: 2015 Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Exploring barriers to Pirfenidone adherence in patients with idiopathic pulmonary fibrosis: a prospective study Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020 Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy Source: Eur Respir J 2016; 47: 889-897 Year: 2016 Late Breaking Abstract - Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension. Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients? Source: Eur Respir Rev 2011; 20: 201-207 Year: 2011 Early COVID-19 lockdown in Greece and idiopathic pulmonary fibrosis: a beneficial “impact” beyond any expectation Source: Eur Respir J, 57 (3) 2003111; 10.1183/13993003.03111-2020 Year: 2021 All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Late Breaking Abstract - Comparative real world effectiveness of triple therapy versus dual bronchodilation in frequently exacerbating patients with COPD Source: International Congress 2018 – COPD exacerbations and bronchiectasis Year: 2018